Table 2.
Phamacolocical blockage of αvβ6 integrin in mice
| Mice group | Genotype | Antibody | n | Result |
|---|---|---|---|---|
| 1 (treatments started at E16.5) | Itgb8–/– | 6.3G9 | 12 | Death at days 11-22; multi-organ inflammation in all |
| Non-KO | 6.3G9 | 12 | Littermates sacrificed in parallel; lung inflammation only | |
| Itgb8–/– | Control (1E6) | 2 | Sacrificed at weeks 6.5 and 9 – no inflammation | |
| Non-KO | Control (1E6) | 2 | Sacrificed at weeks 6.5 and 9 – no inflammation | |
| 2 (treatments started at P0) | Itgb8–/– | 6.3G9 | 8 | Death at days 11-26; multi-organ inflammation in all |
| Non-KO | 6.3G9 | 8 | Littermates sacrificed in parallel; lung inflammation only | |
| Itgb8–/– | Control (1E6) | 3 | One mouse death at day 25, two mice sacrificed at day 25; no inflammation | |
| Non-KO | Control (1E6) | 3 | Sacrificed at day 25; no inflammation | |
| 3 (treatments started at P3) | Itgb8–/– | 6.3G9 | 4 | Death at days 35-101; variable inflammation |
| Non-KO | 6.3G9 | 4 | Littermates sacrificed in parallel; lung inflammation only |
Mice groups 1, 2 and 3, three protocols used to treat mice with either mAb 6.3G9 against αvβ6 integrin or mAb 1E6 (control). Group 1 mice were treated prenatally by injecting pregnant females with 10 mg/kg of 6.3G9 (or control antibody) on E16.5 and E18.5, and then postnatally beginning on P3 and continuing weekly. Group 2 mice were first injected on the day of birth (P0) and then weekly. Group 3 mice were first injected on P3 and then weekly